J&J gets approval to buy Synthes, as EC accepts its commitment to sell trauma business
The European Commission has approved Johnson & Johnson’s proposed acquisition of Synthes, subject to J&J selling their trauma business. Johnson & Johnson had submitted commitments to selling their European trauma device business, given the Commission’s findings of J&J and Synthes’ market shares and the reluctance of surgeons in switching suppliers.
Following an investigation into the market for orthopedic medical devices, the Commission found that strong competitors for spine, shoulder replacement and cranio-maxillofacial devices would remain after the transaction.
Full content: EC Press Release
Related content: Analyzing Medical Device Mergers
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Hess Shareholders Approve $53 Billion Merger with Chevron
May 28, 2024 by
CPI
EU Regulators Engage with Telegram as App Nears Critical Usage Threshold
May 28, 2024 by
CPI
EEX Offers Remedies to Address EU Antitrust Concerns Over Nasdaq Deal
May 28, 2024 by
CPI
BRG Expands European Competition Practice with New Expert Team in Brussels
May 28, 2024 by
CPI
UK Law Empowers Regulators to Fine Big Tech Without Court Approval
May 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI